For further development of successors of Agomelatine through modulation of its pharmacokinetic properties, we report herein the design, synthesis and pharmacological results of a new family of melatonin receptor ligands. Issued from the introduction of quinazoline and phthalazine scaffolds carrying an ethyl amide lateral chain and a methoxy group as bioisosteric ligands analogues of previously developed Agomelatine. The biological activity of the prepared analogues was compared with that of Agomelatine. Quinazoline and phthalazine rings proved to be a versatile scaffold for easy feasible MT1 and MT2 ligands. Potent agonists with sub-micromolar binding affinity were obtained. However, the presence of two nitrogen atoms resulted in compounds with lower affinity for both MT1 and MT2, in comparison with the parent compound, balanced by the exhibition of good pharmacokinetic properties.

中文翻译：

---

喹唑啉和酞嗪衍生物作为阿戈美拉汀的新型褪黑激素受体配体类似物。

为了通过调节其药代动力学特性来进一步开发阿戈美拉汀的继任者，我们在此报告了一个新的褪黑激素受体配体家族的设计、合成和药理学结果。由于引入了喹唑啉和酞嗪支架，该支架带有一个乙酰胺侧链和一个甲氧基，作为先前开发的阿戈美拉汀的生物等排配体类似物。将制备的类似物的生物活性与阿戈美拉汀的生物活性进行比较。喹唑啉和酞嗪环被证明是一种多功能支架，可用于简单可行的 MT1 和 MT2 配体。获得了具有亚微摩尔结合亲和力的有效激动剂。然而，与母体化合物相比，两个氮原子的存在导致化合物对 MT1 和 MT2 的亲和力较低，